Tau positron emission tomography imaging in tauopathies: The added hurdle of off‐target binding
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Ligands targeting tau for use with positron emission tomography have rapidly been developed during the past several years, enabling the in vivo study of tau pathology in patients with Alzheimer's disease and related non‐Alzheimer's disease tauopathies. Several candidate compounds have been developed, showing good in vitro characteristics with respect to their ability to bind tau deposits; off‐target binding, however, has also been observed. In this short commentary, we briefly summarize the available in vivo and in vitro evidence pertaining to their off‐target binding and discuss the different approaches that are needed for the future development of tau positron emission tomography tracers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330 · cited 1×
“In vitro binding studies performed so far using both immunohistochemistry and autofluorescence have shown a complex pattern of binding for tau tracers, including specific binding to neurofibrillary tangles [5,18,19], but also off-target binding in the choroid plexus, to melanin and lipofusein structures [5], mineraliz…”
Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies
Marquié, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Antón‐Fernández, A., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24844 · Cited by 190
Schonhaut, D. R., McMillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., Tsai, R., Winer, J., Russell, D. S., Litvan, I., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25060 · Cited by 175
Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease
Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., Tago, T., Tomita, N., Watanuki, S., Hiraoka, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197426 · Cited by 168
Vermeiren, C., Motte, P., Viot, D., Mairet‐Coello, G., Courade, J., Citron, M., Mercier, J., Hannestad, J., & Gillard, M. (2018) · Movement Disorders · doi:10.1002/mds.27271 · Cited by 143 · cited 13×
“Keywords: Tau PET; Off-target; AV-1451; THK5351; THK5117; THK5317; T807; MAO-B; MAO-A; Flortaucipir”
InfluentialHall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132
Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy
Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., Yanai, K., Kudo, Y., Arai, H., Furumoto, S., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13164 · Cited by 92
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T. D., Arnold, R., Allinson, K. S. J., Coles, J. P., Aigbirhio, F. I., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316402 · Cited by 84
Ikonomovic, M. D., Abrahamson, E. E., Price, J. C., Mathis, C. A., & Klunk, W. E. (2016) · Annals of Neurology · doi:10.1002/ana.24706 · Cited by 81
MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
Hansen, A. K., Brooks, D. J., & Borghammer, P. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1143-1 · Cited by 51
Cited by
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Self-citationSpread of pathological tau proteins through communicating neurons in human Alzheimer’s disease
Vogel, J. W., Iturria-Medina, Y., Strandberg, O. T., Smith, R., Levitis, E., Evans, A. C., Hansson, O., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15701-2 · Cited by 516
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
Franzmeier, N., Neitzel, J., Rubinski, A., Smith, R., Strandberg, O., Ossenkoppele, R., Hansson, O., Ewers, M., (ADNI), A. D. N. I., Weiner, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14159-1 · Cited by 333
A walk through tau therapeutic strategies
Jadhav, S., Avila, J., Schöll, M., Kovacs, G. G., Kövari, E., Skrabana, R., Evans, L. D., Kontsekova, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 290
Metadata
- Authors
- Lemoine, L., Leuzy, A., Chiotis, K., Rodriguez‐Vieitez, E., & Nordberg, A.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 10
- Issue
- 1
- Pages
- 232-236
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2789785835
- Cited by
- 139
- References
- 17
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.